about
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemiaNUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitorsPrognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists.Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.Mixed phenotype acute leukaemia with Burkitt-like cells and positive peroxidase cytochemistry.Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.SNP-array lesions in core binding factor acute myeloid leukemia.High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatoryA 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemiaSomatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemiaA novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemiaIKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic LeukemiaUnlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNAPolycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemiaBaseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignanciesCytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotypeControversies about germline RUNX1 missense variantsThe stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemiaIncreased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literatureInherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemiaMature neutrophils with Auer rod bundles in CBFB-MYH11-positive acute myeloid leukemiaMolecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study GroupGermline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AMLAcute Myeloid Leukemia: The Good, the Bad, and the UglyFamilial myeloid malignancies with germline TET2 mutationMutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemiaWhen leukocytes bite off more than they can chewClofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeB-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL
P50
Q33753763-0C5EFA3A-C171-4A36-9655-87222717AE48Q33758306-7CBF1CED-7F3B-4111-A7B2-C3C1F61A8236Q34106837-6CACE07D-D117-42C5-9DFD-F0FB3F914C2CQ36188346-53A5ACF7-7C46-4F08-A5F2-FA1621654AE0Q37216300-CD64A13D-7896-4557-B17E-BECC21EE552FQ38263126-130E2EDC-A30A-4028-85EA-1FBA60ABB75AQ39000607-47C0BD71-EC20-43BA-AF53-AE2F3334FB9BQ40897451-ADBC4311-2D82-4AEA-A4FD-97986CD1E878Q45792742-F37CA959-A777-4913-AA6B-78B8B7E994EFQ47159669-9AD7B866-FA47-4BA2-92F0-00BFCCB7AAA6Q48184463-7EA4B4B0-445F-44DD-9FE4-558A126C8B73Q49787424-8F246D95-6795-4E75-A30C-B0B10223C9EAQ50111310-2B1C6056-50B2-4D7F-A4C9-0D4BB548A418Q50230268-DD4E3F01-B53B-471B-A055-8700DFD81792Q54114465-278B8FDF-9F46-40E4-9BCE-B6831A73CFC6Q54210991-DF1B539E-F517-454A-B7E9-4E92C44FE9BAQ54550221-8A97B0A6-0036-465A-9D8B-A0356EF92966Q57784507-2B601EE5-DDAC-4039-B08F-D92DC5342CA5Q58553077-D161D315-079B-4C38-BD99-109CCAEF2721Q59639979-097259CC-B175-48E3-96E0-15F25EE9688AQ59797115-29215D9E-AD23-45BD-93AC-9FE9669E79AAQ64100618-F761B484-B99D-4FD0-BFF8-2AE087397258Q87083296-69E0AC50-1CC2-4185-BE75-9954202D2F39Q87421398-D311A030-0680-4A9B-9E73-FC61F462D72DQ89297785-88068D42-FAC9-414B-A6F3-363ED58492BBQ89903544-1971D0A9-2452-4BB6-A313-0A130B44EE90Q90727443-26DBA395-E92A-45AB-949E-27E27D1EC1C7Q90776775-92BE1364-E8E0-4A14-ABC4-B8EE77DBAD39Q90841525-686FF02A-68FA-469E-9F11-3A952A87A823Q90925564-3706D852-F55E-45D0-89F3-7614A05189BEQ91165027-183FF8C4-F383-4FCA-B8DC-DB9DE5A25E33Q91265156-C6E268C0-39D6-43C6-8867-789968FA2D67Q91274017-DEB3C5B5-AB8D-450A-AAA0-F2121B46D006Q91274224-C5D05FC1-16A3-4AE0-97BC-9F0B917A63D3Q91546528-164E5528-9E83-43A8-B4EA-71131D6EB2ABQ91892264-9A14A23A-4FBC-4AFF-8E87-8555858DF980Q92276492-30A65F40-6631-4DEC-A334-B5BBF400B5BEQ92428033-229DF952-7649-43CF-8DF8-28EB1601758FQ92443326-1BA9D0FC-0F4A-4045-968F-9DEA18B22D3CQ92541804-07E33BBB-6F18-41CD-A06A-B892C54BE59A
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3927-1022
@en
name
Nicolas Duployez
@ast
Nicolas Duployez
@en
Nicolas Duployez
@es
Nicolas Duployez
@nl
type
label
Nicolas Duployez
@ast
Nicolas Duployez
@en
Nicolas Duployez
@es
Nicolas Duployez
@nl
prefLabel
Nicolas Duployez
@ast
Nicolas Duployez
@en
Nicolas Duployez
@es
Nicolas Duployez
@nl
P214
P106
P108
P21
P214
P31
P496
0000-0002-3927-1022
P7859
viaf-305421548